Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01154452 · OUTCOME

Progression-free Survival (PFS)

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma · Source last updated 2018-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
6 weeks

What was measured

Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)

Groups in this outcome

Arm I (Gamma-secretase Inhibitor RO4929097)

Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Gamma-Secretase Inhibitor RO4929097: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies

Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)

Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Gamma-Secretase Inhibitor RO4929097: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Vismodegib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Gamma-secretase Inhibitor RO4929097)35
Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)33

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I (Gamma-secretase Inhibitor RO4929097)60Not reportedNot reportedNot reportedNot reported
Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)60Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        60
      2. group Id
        OG001
        value
        60
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    2. group Id
      OG001
      value
      33
    units
    Participants
description
Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)
groups
  1. description
    Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Gamma-Secretase Inhibitor RO4929097: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
    id
    OG000
    title
    Arm I (Gamma-secretase Inhibitor RO4929097)
  2. description
    Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Gamma-Secretase Inhibitor RO4929097: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Vismodegib: Given PO
    id
    OG001
    title
    Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)
param Type
NUMBER
reporting Status
POSTED
time Frame
6 weeks
title
Progression-free Survival (PFS)
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice